Bromocriptine; Cabergoline/Selected Macrolide Antibiotics Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
When these two medicines are taken together, your body may not process bromocriptine or cabergoline properly.
What might happen:
Your blood levels of your bromocriptine or cabergoline may increase and may cause increased side effects.
What you should do about this interaction:
Contact your healthcare professional (e.g. doctor or pharmacist) right away about using these medicines together. Your doctor may not want you to take bromocriptine or cabergoline while you are taking your antifungal.If you experience nausea, constipation, loss of appetite, dry mouth, vomiting, abnormal involuntary movements, headache, dizziness, weakness, or fatigue contact your healthcare professional.Your healthcare professionals may already be aware of this drug interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Ketek (telithromycin) US prescribing information. Sanofi-Aventis U.S. LLC November, 2015.
- 2.Cycloset (bromocriptine mesylate) tablets, US prescribing information. Veroscience LLC February 2, 2016.
- 3.Dostinex (cabergoline) US prescribing information. Pfizer December, 2019. 4.Lu WJ, Huang K, Lai ML, Huang JD. Erythromycin alters the pharmacokinetics of bromocriptine by inhibition of organic anion transporting polypeptide C-mediated uptake. Clin Pharmacol Ther 2006 Oct;80(4):421-2.
- 4.This information is based on or an extract from the UW Metabolism and Transport Drug Interaction Database (DIDB) Platform, Copyright University of Washington 1999-2019..
- 5.Nelson MV, Berchou RC, Kareti D, LeWitt PA. Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine. Clin Pharmacol Ther 1990 Jun;47(6):694-7.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.